Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
128M
-
Number of holders
-
239
-
Total 13F shares, excl. options
-
93.9M
-
Shares change
-
-332K
-
Total reported value, excl. options
-
$6.41B
-
Value change
-
+$1.2M
-
Put/Call ratio
-
2.13
-
Number of buys
-
148
-
Number of sells
-
-89
-
Price
-
$68.30
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q3 2022
295 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q3 2022.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 239 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.9M shares
of 128M outstanding shares and own 73.52% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (10.1M shares), WELLINGTON MANAGEMENT GROUP LLP (9.96M shares), VANGUARD GROUP INC (9.03M shares), BlackRock Inc. (7.09M shares), T. Rowe Price Investment Management, Inc. (5.52M shares), EcoR1 Capital, LLC (5.18M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.35M shares), STATE STREET CORP (2.96M shares), JENNISON ASSOCIATES LLC (2.53M shares), and Octagon Capital Advisors LP (2.5M shares).
This table shows the top 239 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.